Virpax Pharmaceuticals Performance
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
The entity has a beta of -0.99, which indicates possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Virpax Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, Virpax Pharmaceuticals is expected to outperform it slightly. Virpax Pharmaceuticals right now has a risk of 0.0%. Please validate Virpax Pharmaceuticals kurtosis and the relationship between the rate of daily change and relative strength index , to decide if Virpax Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Virpax Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 9.1 B |
Virpax |
Virpax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 25.00 in Virpax Pharmaceuticals on April 25, 2025 and sell it today you would earn a total of 0.00 from holding Virpax Pharmaceuticals or generate 0.0% return on investment over 90 days. Virpax Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Virpax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Virpax Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Virpax Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Virpax Pharmaceuticals, and traders can use it to determine the average amount a Virpax Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VRPX |
Based on monthly moving average Virpax Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Virpax Pharmaceuticals by adding Virpax Pharmaceuticals to a well-diversified portfolio.
Virpax Pharmaceuticals Fundamentals Growth
Virpax Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Virpax Pharmaceuticals, and Virpax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Virpax Pink Sheet performance.
| Return On Equity | -23.65 | ||||
| Return On Asset | -1.35 | ||||
| Current Valuation | (1.21 M) | ||||
| Shares Outstanding | 1.24 M | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (12.08 B) | ||||
| Cash And Equivalents | 26.06 M | ||||
| Cash Per Share | 2.22 X | ||||
| Total Debt | 2.47 B | ||||
| Debt To Equity | 0.11 % | ||||
| Book Value Per Share | (1.53) X | ||||
| Cash Flow From Operations | (16.71 B) | ||||
| Earnings Per Share | (71.00) X | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (71.61 B) | ||||
About Virpax Pharmaceuticals Performance
Evaluating Virpax Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Virpax Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Virpax Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Things to note about Virpax Pharmaceuticals performance evaluation
Checking the ongoing alerts about Virpax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Virpax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Virpax Pharmaceuticals is not yet fully synchronised with the market data | |
| Virpax Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Virpax Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.07 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Virpax Pharmaceuticals currently holds about 26.06 M in cash with (16.71 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Virpax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Virpax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Virpax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Virpax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Virpax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Virpax Pharmaceuticals' pink sheet. These opinions can provide insight into Virpax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance |